CliffBio
small molecule

BORTEZOMIB

BORTEZOMIB

Loss of exclusivity—loss of exclusivity
CompanyApotex →See this company's full patent-cliff portfolio

Drug detail

Brand nameBORTEZOMIB
Active ingredientBORTEZOMIB
Strength3.5MG/VIAL
Dosage formINJECTABLE
RouteINTRAVENOUS, SUBCUTANEOUS
ModalitySmall molecule
FDA approvalMay 2022
Marketing statusRX

More from Apotex

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.